The abstract is read at the publisher; the summary is JClub's.
Gender was reported in 553 of 58,007 ClinicalTrials.gov interventional trials (0.95%), while sex was reported in 57,683 (99.44%), with gender disclosure concentrated in specific trial types.
- Why it matters: Limited reporting of both sex and gender restricts characterization of participant experiences and hampers comparisons between trial female enrollment and the female burden of disease.
- What they did: In a cross-sectional analysis of 58,007 trials with primary completion on/after September 27, 2008 and results posted from January 1, 2009 to April 30, 2026, investigators assessed sex and gender reporting and calculated female participation-to-prevalence ratios (PPR).
- The result: Median PPR across 10 conditions ranged from 0.68 for chronic obstructive pulmonary disease to 1.05 for obesity, and 43.0% of prevalent-condition combinations (6,917 of 16,097) reached PPR ≥ 0.90, with NIH-funded trials more likely (OR, 1.22) and government-funded less likely (OR, 0.26).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.